newsfilter
← Latest News
GlobeNewswire·

Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy TN-201 and TN-401 Program Updates on Upcoming